Burrill Life Sciences Capital Fund III – Securities Investigation
Are you concerned about your investment in Burrill Life Sciences Capital Fund III? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Arbitration claim against the brokerage firm that sold you the investment.
According to SEC filings, Burrill Life Sciences Capital Fund III, based in San Francisco, CA, filed a Form D to raise capital from investors.
Burrill Life Sciences Capital Fund III is a Regulation D private placement investment. Investments such as these are typically sold by brokerage firms in exchange for a large up front commission. High fees can range from 7-10%, as well as additional “due diligence fees” that can range from 1-3%.
The problem with private placement investments such as Burrill Life Sciences Capital Fund III is that they typically involve a high degree of risk. They are also often sold as unregistered securities which lack the same regulatory oversight as more traditional investment products like stocks or bonds.
Investigating Potential Claims
The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk private placements, like Burrill Life Sciences Capital Fund III to investors.
Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.
If you have concerns regarding your investment in Burrill Life Sciences Capital Fund III and would like to speak with a securities attorney about your options, please call The White Law Group at 888-637-5510.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.
For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.
Tags: Burrill Life Sciences Capital Fund III, Burrill Life Sciences Capital Fund III complaints, Burrill Life Sciences Capital Fund III default, Burrill Life Sciences Capital Fund III help, Burrill Life Sciences Capital Fund III high commissions, Burrill Life Sciences Capital Fund III information, Burrill Life Sciences Capital Fund III investigation, Burrill Life Sciences Capital Fund III investment, Burrill Life Sciences Capital Fund III investment losses, Burrill Life Sciences Capital Fund III investor relations, Burrill Life Sciences Capital Fund III investors, Burrill Life Sciences Capital Fund III losses, Burrill Life Sciences Capital Fund III ppm, Burrill Life Sciences Capital Fund III private placement, Burrill Life Sciences Capital Fund III prospectus, Burrill Life Sciences Capital Fund III recovery options, Burrill Life Sciences Capital Fund III risk, Burrill Life Sciences Capital Fund III stock information, Burrill Life Sciences Capital Fund III update Last modified: December 8, 2022